BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, April 20, 2026
Home » Newsletters » BioWorld Science

BioWorld Science

June 7, 2017

View Archived Issues

Pfizer begins first-in-human study of PF-06730512

Read More

Bird Rock Bio completes phase I study of namacizumab

Read More

Synereca Pharmaceuticals develops colistin potentiators for resistant Gram-negative infections

Read More

AbCellera Biologics enters influenza vaccine research collaboration with Sanofi Pasteur

Read More

Marina Biotech acquires Prestalia from Symplmed Pharmaceuticals

Read More

FDA approves 2-month dosing option of Alkermes' Aristada

Read More

AstraZeneca agrees to divest ex-Japanese Zomig rights to Grunenthal

Read More

NanoViricides reports promising findings for topical drug candidates for shingles

Read More

First patients in phase II study respond to encochleated amphotericin B

Read More

FDA grants fast track status to Pfizer's Vyndaqel for TTR-CM

Read More

Abiraterone acetate improves survival in men starting hormone therapy for prostate cancer

Read More

Midatech licenses Novartis' panobinostat for evaluation in brain cancers

Read More

Viking Therapeutics reports promising in vivo data on VK-2809 in NASH

Read More

Living Cell Technologies gives update on phase I/IIa study of NTCELL in Parkinson's disease

Read More

Phase II data reported for tazemetostat in synovial sarcoma

Read More

Poxel reports additional results from the phase IIb imeglimin study

Read More

Warner Babcock Institute for Green Chemistry identifies new beta-amyloid aggregation inhibitors

Read More

Oppilan Pharma patents sphingosine 1-phosphate receptor 1 agonists

Read More

Daratumumab shows promise for newly diagnosed multiple myeloma patients

Read More

RQx Pharmaceuticals, Genentech describe novel signal peptidase IB inhibitors

Read More

Araxes Pharma synthesizes new KRAS inhibitors

Read More

CIMA describes novel DNMT/EHMT2 inhibitors

Read More

Novo Nordisk receives European approval for Refixia

Read More

R-Pharm CJSC discloses new tyrosine-protein kinase JAK inhibitors

Read More

Hemophilia A gene therapy from Sangamo and Pfizer receives E.U. orphan drug designation

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for April 17, 2026.
  • Man holding raised arm with illustrated overlay of nerves

    Biohaven reports details on discovery of BHV-2100

    BioWorld Science
    Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
  • New GABA(B) receptor PAMs revealed in Addex Pharma patents

    BioWorld Science
    Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...
  • Elderly woman holding illustration of brain with missing puzzle piece

    Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’

    BioWorld
    The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
  • Novel caspase-2 inhibitor shows in vivo neuroprotective effects

    BioWorld Science
    Caspase-2-mediated cleavage of tau at Asp314 generates a neurotoxic fragment, Δtau314, that drives early synaptic dysfunction in Alzheimer’s disease (AD) and...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing